The U.S. Food and Drug Administration has approved expanded use of Amgen's drug, Uplizna, to help reduce the risk of flares ...

Amgen (NasdaqGS:AMGN) experienced a significant 18.62% price increase over the last quarter, coinciding with the recent FDA ...

The U.S. Food and Drug Administration has approved expanded use of Amgen's drug, Uplizna, to help reduce the risk of flares ...

Shares of Amgen Inc. AMGN rallied 1.36% to $309.85 Thursday, on what proved to be an all-around dismal trading session for ...

Amgen is a leading biopharmaceutical company that develops innovative medicines in areas with significant unmet needs. Read ...

A federal judge has thrown out Amgen’s lawsuit against the state board empowered to set price ceilings on prescription drugs ...

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take ...

The FDA approved Amgen ’s anti-CD19 therapy Uplizna Thursday for use in patients with IgG4-related disease. Uplizna is the ...

Amgen (NASDAQ: NASDAQ:AMGN) announced that the U.S. Food and Drug Administration (FDA) has granted an expanded label approval ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

With a label expansion for Uplizna pushing the drug into an untouched rare disease market, Amgen is getting its money’s worth ...

On CNBC's “ Halftime Report Final Trades ,” Jenny Van Leeuwen Harrington of Gilman Hill Asset Management, LLC said Sabra ...